IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar

Switching to CT-P13, an infliximab biosimilar, is safe and well tolerated in patients with IBD whose disease is in remission, researchers say.Reuters Health Information

Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news